SEQIRUS VACCINES LIMITED

03970089
Active Merseyside

Manufacture of basic pharmaceutical products

671 employees website.com
Life sciences and medical technology Manufacture of basic pharmaceutical productsManufacture of pharmaceutical preparations
S

SEQIRUS VACCINES LIMITED

03970089

Manufacture of basic pharmaceutical products

Founded 11 Apr 2000 Active Merseyside, United Kingdom 671 employees website.com
Life sciences and medical technology Manufacture of basic pharmaceutical productsManufacture of pharmaceutical preparations

Previous Company Names

NOVARTIS VACCINES AND DIAGNOSTICS LIMITED 3 May 2006 — 9 Nov 2015
CHIRON VACCINES LIMITED 8 Nov 2004 — 3 May 2006
EVANS VACCINES LIMITED 4 Sept 2000 — 8 Nov 2004
ALNERY NO. 1979 LIMITED 11 Apr 2000 — 4 Sept 2000
Accounts Submitted 29 Mar 2026 Next due 31 Mar 2026 4 months overdue
Confirmation Submitted 20 Mar 2026 Next due 12 Mar 2027 8 months remaining
Net assets £144M £10M 2025 year on year
Total assets £254M £3M 2025 year on year
Total Liabilities £110M £13M 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Registered Address

Gaskill Road Liverpool Merseyside L24 9GR

Website

www.example.com

Full company profile for SEQIRUS VACCINES LIMITED (03970089), an active life sciences and medical technology company based in Merseyside, United Kingdom. Incorporated 11 Apr 2000. Manufacture of basic pharmaceutical products. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jul → 30 Jun 2025
Type full
Next accounts 30 Jun 2025
Due by 31 Mar 2026 4 months overdue

Balance Sheet & P&L (2013–2025)

Cash in Bank

£4.30M

Increased by £1.90M (+79%)

Net Assets

£143.90M

Increased by £9.60M (+7%)

Total Liabilities

£110.20M

Decreased by £12.90M (-10%)

Turnover

£175.20M

Decreased by £22.50M (-11%)

Employees

671

Decreased by 4 (-1%)

Debt Ratio

43%

Decreased by 5 (-10%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
30 Jun Year End
2024
30 Jun Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

Seqirus Vaccines Holdings Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased
Active
Notified 13 Mar 2026
Nature of Control
  • Ownership Of Shares 75 To 100 Percent
  • Voting Rights 75 To 100 Percent
  • Voting Rights 75 To 100 Percent As Firm
  • Right To Appoint And Remove Directors
Ceased

Group Structure

Group Structure

SEQIRUS LIMITED united kingdom
SEQIRUS VACCINES LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

1 freehold 5 leasehold 6 total
AddressTenurePrice PaidDate Added
8 Renaissance Way, Liverpool (L24 9PS) LIVERPOOL
Leasehold-20 Mar 2020
Novartis Vaccines & Diagnostics, Gaskill Road, Liverpool (L24 9GR) LIVERPOOL
Freehold-9 Dec 2014
Unit 4, Boulevard Industry Park, Speke, Liverpool LIVERPOOL
Leasehold-10 Jul 2009
Unit 5a, Boulevard Industry Park, Speke, Liverpool LIVERPOOL
Leasehold-19 Apr 2007
land and buildings on the North side of Speke Boulevard, Liverpool LIVERPOOL
Leasehold-5 Sept 2001
8 Renaissance Way, Liverpool (L24 9PS)
Leasehold
Added 20 Mar 2020
District LIVERPOOL
Novartis Vaccines & Diagnostics, Gaskill Road, Liverpool (L24 9GR)
Freehold
Added 9 Dec 2014
District LIVERPOOL
Unit 4, Boulevard Industry Park, Speke, Liverpool
Leasehold
Added 10 Jul 2009
District LIVERPOOL
Unit 5a, Boulevard Industry Park, Speke, Liverpool
Leasehold
Added 19 Apr 2007
District LIVERPOOL
land and buildings on the North side of Speke Boulevard, Liverpool
Leasehold
Added 5 Sept 2001
District LIVERPOOL

Documents

Company Filings

DateCategoryDescriptionDocument
29 Mar 2026AccountsAnnual accounts made up to 30 Jun 2025
20 Mar 2026Persons With Significant ControlCessation of Seqirus Vaccines Holdings Limited as a person with significant control on 13 Mar 2026
20 Mar 2026Confirmation StatementConfirmation statement made on 26 Feb 2026 with no updates
20 Mar 2026Persons With Significant ControlSeqirus Limited notified as a person with significant control
16 Mar 2026OfficersChange to director Mr Christopher James Thorpe on 19 Aug 2024
29 Mar 2026 Accounts

Annual accounts made up to 30 Jun 2025

20 Mar 2026 Persons With Significant Control

Cessation of Seqirus Vaccines Holdings Limited as a person with significant control on 13 Mar 2026

20 Mar 2026 Confirmation Statement

Confirmation statement made on 26 Feb 2026 with no updates

20 Mar 2026 Persons With Significant Control

Seqirus Limited notified as a person with significant control

16 Mar 2026 Officers

Change to director Mr Christopher James Thorpe on 19 Aug 2024

Recent Activity

Latest Activity

Annual accounts made up to 30 Jun 2025

3 months ago on 29 Mar 2026

Cessation of Seqirus Vaccines Holdings Limited as a person with significant control on 13 Mar 2026

3 months ago on 20 Mar 2026

Confirmation statement made on 26 Feb 2026 with no updates

3 months ago on 20 Mar 2026

Seqirus Limited notified as a person with significant control

3 months ago on 20 Mar 2026

Change to director Mr Christopher James Thorpe on 19 Aug 2024

3 months ago on 16 Mar 2026